Upto 60% Off on UPSC Online Courses

Avail Now

WHO Prequalifies Second Dengue Vaccine

Context

The World Health Organisation (WHO) recently announced the prequalification of a second vaccine for dengue, called TAK-003, made by a Japanese drug maker.

Live Attenuated Vaccines

Live vaccines are derived from “wild” viruses or bacteria which have been attenuated (weakened) in a laboratory, usually by repeated culturing. For example, the measles virus used as a vaccine today was isolated from a child with measles disease in 1954.

WHO Prequalifies new Dengue Vaccine

  • WHO has prequalified a second vaccine for dengue, known as TAK-003, made by the Japanese drug maker Takeda Pharmaceuticals.
  • Nature: It is a live-attenuated vaccine containing weakened versions of the four serotypes of the virus that cause dengue. Thus it helps the body to build immunity against all the four dengue viruses. 
  • Target Age Group: TAK-003 can be administered to children aged 6 to 16 years, with a high dengue burden and transmission intensity.
  • Dosage: The vaccine should be administered in a 2-dose schedule with a 3-month interval between doses, as per the WHO.
  • Global Approval Status: The UK, Brazil, Argentina, Indonesia and Thailand have also approved TAK-OO3.
  • First Vaccine: The WHO had previously prequalified the Dengvaxia CYD-TDV vaccine against dengue, developed by Sanofi Pasteur.
    • It was also a live, attenuated dengue virus which has to be administered in people of ages 9 to 16.

Enroll now for UPSC Online Course

India’s DNA Vaccine Candidate against Dengue

  • The Serum Institute of India made major progress in the development of India’s first and only DNA vaccine candidate for dengue fever.
  • The Vaccine is under preliminary trial stage and has given promising results.

DNA Vaccines:

  • DNA Vaccines puts a specific DNA sequence that codes for an antigen into an organism’s cells to trigger an immune response.
  • Dengue is caused by four closely related viruses (DEN-1, DEN-2, DEN-3, and DEN-4), known as serotypes
  • Infection with one serotype provides lifelong protection against it but not the others, necessitating a vaccine that targets all four.

What is Dengue?

Dengue is a mosquito-borne tropical disease caused by the dengue virus (Genus Flavivirus), transmitted by several species of mosquito within the genus Aedes, principally Aedes aegypti.

  • Causative Agent: It is a tropical disease caused by the dengue virus (Genus Flavivirus). It is spread through the bite of infected Aedes species (Ae. aegypti or Ae. albopictus) mosquito.
    • These mosquitoes also spread Chikungunya, Yellow fever and Zika viruses
  • Serotypes of Dengue: There are 4 distinct, but closely related, serotypes (separate groups within a species of microorganisms that all share a similar characteristic) of the virus that cause dengue (DEN-1, DEN-2, DEN-3 and DEN-4).
  • Vulnerability: It is estimated that there are over 100 to 400 million cases of dengue worldwide each year and 3.8 billion people living in dengue-endemic countries, most of which are in Asia, Africa, and the Americas.
  • Symptoms: High fever, headache, body aches, nausea and rash. Severe dengue can cause belly pain, vomiting, bleeding from the nose or gums, and extreme fatigue
  • Control and Prevention: Recently, the World Mosquito Program used mosquitoes infected with Wolbachia bacteria to successfully control dengue in Indonesia.

Significance of Prequalification Status

  • Assurance of Quality, Safety, and Efficacy: WHO prequalification confirms that the vaccine meets rigorous international standards for quality, safety, and efficacy.
  • Global Usage and Acceptance: This status allows the vaccine to be used globally, especially beneficial for low- and middle-income countries where such rigorous evaluation might not be feasible locally.
  • Facilitates Wider Distribution: Prequalification enables the vaccine’s inclusion in procurement processes by UN agencies and other global health organizations, thus promoting wider distribution.
  • Support for Public Health Programs: The approval aids in the integration of the vaccine into public health programs, enhancing disease prevention strategies worldwide.

Enroll now for UPSC Online Classes

Must Read
NCERT Notes For UPSC UPSC Daily Current Affairs
UPSC Blogs UPSC Daily Editorials
Daily Current Affairs Quiz Daily Main Answer Writing
UPSC Mains Previous Year Papers UPSC Test Series 2024

 

Print Friendly, PDF & Email

To get PDF version, Please click on "Print PDF" button.

Print Friendly, PDF & Email

 Final Result – CIVIL SERVICES EXAMINATION, 2023.   Udaan-Prelims Wallah ( Static ) booklets 2024 released both in english and hindi : Download from Here!     Download UPSC Mains 2023 Question Papers PDF  Free Initiative links -1) Download Prahaar 3.0 for Mains Current Affairs PDF both in English and Hindi 2) Daily Main Answer Writing  , 3) Daily Current Affairs , Editorial Analysis and quiz ,  4) PDF Downloads  UPSC Prelims 2023 Trend Analysis cut-off and answer key

THE MOST
LEARNING PLATFORM

Learn From India's Best Faculty

      

 Final Result – CIVIL SERVICES EXAMINATION, 2023.   Udaan-Prelims Wallah ( Static ) booklets 2024 released both in english and hindi : Download from Here!     Download UPSC Mains 2023 Question Papers PDF  Free Initiative links -1) Download Prahaar 3.0 for Mains Current Affairs PDF both in English and Hindi 2) Daily Main Answer Writing  , 3) Daily Current Affairs , Editorial Analysis and quiz ,  4) PDF Downloads  UPSC Prelims 2023 Trend Analysis cut-off and answer key

Quick Revise Now !
AVAILABLE FOR DOWNLOAD SOON
UDAAN PRELIMS WALLAH
Comprehensive coverage with a concise format
Integration of PYQ within the booklet
Designed as per recent trends of Prelims questions
हिंदी में भी उपलब्ध
Quick Revise Now !
UDAAN PRELIMS WALLAH
Comprehensive coverage with a concise format
Integration of PYQ within the booklet
Designed as per recent trends of Prelims questions
हिंदी में भी उपलब्ध

<div class="new-fform">







    </div>

    Subscribe our Newsletter
    Sign up now for our exclusive newsletter and be the first to know about our latest Initiatives, Quality Content, and much more.
    *Promise! We won't spam you.
    Yes! I want to Subscribe.